BioSpace News Archive

Santen Pharmaceutical Co., Ltd. announced on March 8 that as part of its initiatives to increase public awareness of glaucoma, it will sponsor activities to be conducted worldwide during World Glaucoma Week from March 10 to 16, 2019.

Sedana Medical AB announced the results of the interim analysis for the company’s pivotal phase III study aimed at getting the candidate drug IsoConDa approved for inhalation sedation in intensive care in Europe.

Bausch Health Companies Inc. announced the results to date of its pending cash tender offers to purchase up to $1,500,000,000 aggregate purchase price of its outstanding notes listed in the table below, as well as the anticipated early settlement date for the Tender Offers on March 11, 2019.

Cerebral Therapeutics announced the closing of a $7.8 million Extension of its Series A financing by institutional investors Granite Point Capital Management, L.P., and Vivo Capital, LLC. This brings the total Series A investment to $11 million.

Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose generic drug company, and Sinotherapeutics Inc., a Shanghai-based generic drug company, announced they have launched a bioequivalent FDA-approved version of Rythmol SR.

Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime of benefit, announced that Geoff McDonough, President and Chief Executive Officer, will present at the Cowen & Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 12:30 p.m. EST in Boston, MA.

TherapeuticsMD, Inc. announced the schedule of oral presentations on clinical data for BIJUVATM and ANNOVERATM, and poster presentations related to menopause symptoms and treatments, at the International Society for the Study of Women’s Sexual Health and the International Society of Sexual Medicine joint annual meeting in Atlanta, GA on March 8-9, 2019.

Rafael Holdings, Inc., has scheduled its report of financial and operational results covering the second quarter of its 2019 fiscal year for Tuesday, March 12, 2019.

Company to Unveil Eight-Story, State-of-the-Art Office Tower and Multi-Level Amenities Center on Corporate Campus

Arena Pharmaceuticals, Inc. presented new Phase 2 data from its investigative drug candidates etrasimod and olorinab at the 14th Congress of European Crohn’s and Colitis Organisation.